NeOnc Technologies Holdings is trading at $3.07, up 8.87% in pre-market, with no clear company-specific catalyst identified.

  • October 26 news outlined a proposed international trial of approximately 500 patients across 30 hospitals in three countries; it described plans, not completed enrollment.
  • The broad-market indicators provided are modestly higher but do not establish a reason for the move.
  • The previous session closed at $2.82, down 13.76%; available coverage described that decline as lacking a clear company-specific catalyst.